Cargando…
Determination of biomarkers associated with neoadjuvant treatment response focusing on colibactin-producing Escherichia coli in patients with mid or low rectal cancer: a prospective clinical study protocol (MICARE)
INTRODUCTION: The management of mid and low rectal cancer is based on neoadjuvant chemoradiotherapy (CRT) followed by standardised surgery. There is no biomarker in rectal cancer to aid clinicians in foreseeing treatment response. The determination of factors associated with treatment response might...
Autores principales: | Taoum, Christophe, Carrier, Guillaume, Jarlier, Marta, Roche, Gwenaelle, Gagniere, Johan, Fiess, Catherine, De forges, Helene, Chevarin, Caroline, Colombo, Pierre-Emmanuel, Barnich, Nicolas, Rouanet, Philippe, Bonnet, Mathilde |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723882/ https://www.ncbi.nlm.nih.gov/pubmed/36460331 http://dx.doi.org/10.1136/bmjopen-2022-061527 |
Ejemplares similares
-
Colibactin: More Than a New Bacterial Toxin
por: Faïs, Tiphanie, et al.
Publicado: (2018) -
Gut Microbiota as Potential Biomarker and/or Therapeutic Target to Improve the Management of Cancer: Focus on Colibactin-Producing Escherichia coli in Colorectal Cancer
por: Veziant, Julie, et al.
Publicado: (2021) -
Cytotoxic necrotizing factor 1 hinders colon tumorigenesis induced by colibactin-producing Escherichia coli in Apc(Min/+) mice
por: Chat, Héloïse, et al.
Publicado: (2023) -
MICAR: multi-inhabitant context-aware activity recognition in home environments
por: Arrotta, Luca, et al.
Publicado: (2022) -
Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?
por: Villéger, Romain, et al.
Publicado: (2019)